| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 03/18/2004 | US20040053986 3,7-Diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias |
| 03/18/2004 | US20040053983 1, 2, 4-tribsubstituted benzenes as inhibitors of 15-lipoxygenase |
| 03/18/2004 | US20040053982 Such as 3-(2-(6-methyl-pyridin-2-ylamino)-5-(1,2,4)triazol-1-yl-thiazol-4 -yl)benzonitrile for treatment of inflammatory or obstrucive airways diseases |
| 03/18/2004 | US20040053979 Indolyl derivatives |
| 03/18/2004 | US20040053977 Such as N-pyridin-2-yl-N'-(1-pyridin-2-yl-ethylidene)hydrazine for increasing erythropoietin levels and vascularization of tissue; antihypoxic agents |
| 03/18/2004 | US20040053976 Terminally-branched polymeric linkers and polymeric conjugates containing the same |
| 03/18/2004 | US20040053975 Combinations of HMG-CoA reductase inhibitors and nicotinic acid compounds and methods for treating hypelipidemia once a day at night |
| 03/18/2004 | US20040053973 Substituted 1,3-thiazole compounds, their production and use |
| 03/18/2004 | US20040053963 Urotensin-II receptor antagonists |
| 03/18/2004 | US20040053958 Di and trifluoro-triazolo-pyridines anti-inflammatory compounds |
| 03/18/2004 | US20040053957 Enzyme inhibitors of the I kappa B kinase, therapeutic treatment of autoimmune diseases, inflammatory diseases and cancer; chemical intermediates, sulfiding, sulfonation, desulfonation, cyclization |
| 03/18/2004 | US20040053955 An immunosuppressants for treating allograft rejection, transplant rejection, psoriasis, and rheumatoid arthritis, a 9,10-dihydro-9-oxo-acridine-3-yl- derivatives |
| 03/18/2004 | US20040053953 Treatment of chemokine mediated diseases |
| 03/18/2004 | US20040053945 Process for the preparation of a pyrazolo[4,3-d]pyrimidine derivative |
| 03/18/2004 | US20040053943 Novel compounds |
| 03/18/2004 | US20040053942 Fused pyrazole derivatives bieng protein kinase inhibitors |
| 03/18/2004 | US20040053941 Substituted pyrazine derivatives |
| 03/18/2004 | US20040053931 Kinase inhibitors; angiogenesis inhibitors, anticancer agents, antiinflammatory agents and chronic obstructive pulmonary disease inhibitors |
| 03/18/2004 | US20040053925 Novel urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use |
| 03/18/2004 | US20040053924 Reacting pyrrolo(2,3-d)pyrimidin-4-one derivative containing a leaving group with a aromatic or heteroaromatic amine, hydroxy, marcaptan etc. in presence of a polar solvent and a catalyst |
| 03/18/2004 | US20040053921 Compounds useful as reversible inhibitors of cysteine proteases |
| 03/18/2004 | US20040053920 Administering to a patient suffering from caspase mediated diseses, an effective amount of a mono,bi or tri-heterocyclic ring containing nitrogen atom attached to ester or thioester to form carbamate group, as caspase inhibitor |
| 03/18/2004 | US20040053917 Reacting cyanophenyl-4-sulfonylchloride with a piperidine-4-oxo in presence of ethylene glycol to form an intermediate, reducing cyano group, followed by amidation, then reacting with an amine to form sulfonamide end |
| 03/18/2004 | US20040053908 Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective |
| 03/18/2004 | US20040053898 For organ specific therapy; for treatment of menopausal symptoms, hormone-deficiency diseases and neurodegenerative diseases |
| 03/18/2004 | US20040053874 Polynucleotide that hybridize with and inhibit gene expression for amphipathic dimeric glycoproteins |
| 03/18/2004 | US20040053869 Stem cell differentiation |
| 03/18/2004 | US20040053853 Topiramate salts and compositions comprising and methods of making and using the same |
| 03/18/2004 | US20040053852 Preventing desensitization of receptors |
| 03/18/2004 | US20040053851 Association of calpain inhibitors and reactive oxygen species trapping agents |
| 03/18/2004 | US20040053842 Cholesterol ester transfer protein inhibitors for use in treating atherosclerosis optionally in combination with other antihypertensive agents |
| 03/18/2004 | US20040053838 Measuring serum IGF-I and/or IGF-I binding protein levels after birth of patient to obtain IGF-I or IGF-I binding protein level and correlating said level with in utero baseline level based on gestational age matched mean levels |
| 03/18/2004 | US20040053833 Relates to regulation of activity of NET (ERP/SAP-2) protein and to compounds which modify or regulate NET protein activity; methods of screening for agonists or antagonists of NET in order to identify new pro- or anti-angiogenic compounds |
| 03/18/2004 | US20040053828 Partial peptide mimetics and methods |
| 03/18/2004 | US20040053825 Inhibit adenylyl cyclase in cells but have little effect on isolated adenylyl cyclase; useful as prodrugs for inhibiting adenylyl cyclase and lowering 3':5'-cAMP in cells, thereby inhibiting adenylyl cyclase dependent effects within cells |
| 03/18/2004 | US20040053819 Normalizing blood glucose levels by maintaining chronic steady state plasma levels of 60-200 picomoles/liter; subcutaneous injection 1-2 times every 24 hours |
| 03/18/2004 | US20040053817 Proinsulin C-peptide is present in an absorbable matrix of polyglycolide-lactide copolymers; antidiabetic agents |
| 03/18/2004 | US20040053281 Comprises enzymatic polypeptide associated with fatty acid metabolism for diagnosing, treating and preventing cancer, neurodegenerative, autoimmune/inflammatory, gastrointestinal and cardiovascular disorders |
| 03/18/2004 | US20040053278 Smad6 and uses thereof |
| 03/18/2004 | US20040053259 Comprises methylated antisense oligonucleotide sequence for regulation of urokinase type plasminogen activator and treatment of cancer |
| 03/18/2004 | US20040053228 Apoptosis inhibitory polypeptides, gene and polynucleotide encoding it and compositions containing the same |
| 03/18/2004 | US20040053206 Using tissue preservation solution to decrease reperfusion injury of an organ during surgery and/or following removal of organ |
| 03/18/2004 | US20040052922 Nutritional and therapeutical preparations having antioxidant activity |
| 03/18/2004 | US20040052873 Bioavailability / bioefficacy enhancing activity of cuminum cyminum and extracts and fractions thereof |
| 03/18/2004 | US20040052870 Cyclooxygenase (COX-2) inhibitors; for treatment/prevention of inflammation; nutraceuticals; for treatment of nervous system disorders |
| 03/18/2004 | US20040052835 Matrix controlled transdermal system for stabile derivatives of ace inhibitors |
| 03/18/2004 | US20040052809 Atherosclerosis; apolipoproteins; induce immunology response |
| 03/18/2004 | US20040052786 Erbb4 antagonists |
| 03/18/2004 | DE10242941A1 New 2-(pyrazolo-(3,4-b)-pyridinyl)-5-pyridinyl-4-pyrimidinylamine derivative, is a soluble guanylate cyclase stimulant useful e.g. for treating cardiovascular diseases, hypertension or ischemia |
| 03/18/2004 | CA2499380A1 Novel vinyl carboxylic acid derivatives and their therapeutical use |
| 03/18/2004 | CA2498297A1 Recombinatant mutants of rhabdovirus and methods of use thereof |
| 03/18/2004 | CA2498296A1 Zinc transporter compositions for the treatment of cardiovascular diseases |
| 03/18/2004 | CA2497979A1 1, 3-diamino-2-hydroxypropane prodrug derivatives |
| 03/18/2004 | CA2497901A1 Furan or thiophene derivative and medicinal use thereof |
| 03/18/2004 | CA2497896A1 Pravastatin pharmaceutical formulations and methods of their use |
| 03/18/2004 | CA2497836A1 A method of modulating endothelial cell activity |
| 03/18/2004 | CA2496891A1 Novel actin-related cytoskeletal protein lacs |
| 03/18/2004 | CA2495284A1 Diarylurea derivatives and their use as chloride channel blockers |
| 03/18/2004 | CA2493974A1 Pharmaceutical dosage form comprising a sulfite compound |
| 03/17/2004 | EP1398313A1 Novel heterocyclic derivatives and medicinal use thereof |
| 03/17/2004 | EP1398036A1 Ganoderma lucidum spores for treatment of autoimmune diseases |
| 03/17/2004 | EP1398033A2 Use of benzodiazepines for treating autoimmune diseases, inflammations, neoplasies, viral infections and atherosclerosis |
| 03/17/2004 | EP1398025A1 Fine inorganic particles having drug included therein, method for preparation thereof and pharmaceutical preparation comprising fine inorganic particles having drug included therein |
| 03/17/2004 | EP1397507A1 Methods and compositions for treating cardiovascular disease using 10218 |
| 03/17/2004 | EP1397385A2 Methods for treating disorders of the nervous and reproductive systems |
| 03/17/2004 | EP1397379A1 Adenosine derivative in polymorph i form |
| 03/17/2004 | EP1397378A1 Adenosine derivative in polymorph ii form |
| 03/17/2004 | EP1397369A1 New use or cyclolignans and new cyclolignans |
| 03/17/2004 | EP1397368A1 New use of specific cyclolignans |
| 03/17/2004 | EP1397365A1 Novel heteroaryl-diazabicyclo-alkanes as cns-modulators |
| 03/17/2004 | EP1397364A1 Novel pyrrole derivatives as pharmaceutical agents |
| 03/17/2004 | EP1397363A1 5-ethyl-imidazotriazinones |
| 03/17/2004 | EP1397361A1 Carboline derivatives as pdev inhibitors |
| 03/17/2004 | EP1397360A1 Azaindoles |
| 03/17/2004 | EP1397359A1 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors |
| 03/17/2004 | EP1397357A2 Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
| 03/17/2004 | EP1397356A1 Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (pai-1) |
| 03/17/2004 | EP1397354A1 Imidazole-2-carboxamide derivatives as raf kinase inhibitors |
| 03/17/2004 | EP1397351A1 Pyrimidine, triazine and pyrazine derivatives as glutamate receptors |
| 03/17/2004 | EP1397348A2 Factor xa inhibitor |
| 03/17/2004 | EP1397341A1 6-(aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (pai-1) |
| 03/17/2004 | EP1397172A1 Safety shield system for prefilled syringes |
| 03/17/2004 | EP1397170A1 Safety shield system for prefilled syringes |
| 03/17/2004 | EP1397160A1 Pharmaceutical composition including ace/nep inhibitors and bioavailability enhancers |
| 03/17/2004 | EP1397150A2 Somatostatin agonists |
| 03/17/2004 | EP1397148A2 Chromium/biotin treatment of dyslipidemia and diet-induced post prandial hyperglycemia |
| 03/17/2004 | EP1397142A2 Pyrimidine inhibitors of phosphodiesterase (pde) 7 |
| 03/17/2004 | EP1397139A1 Pharmaceutical combinations |
| 03/17/2004 | EP1397137A1 Hydantion derivatives as inhibitors of matrix metalloproteinases |
| 03/17/2004 | EP1397127A1 Solid pharmaceutucal formulations comprising modafinil |
| 03/17/2004 | EP1242406B1 Novel compounds |
| 03/17/2004 | EP1242364B1 Adamantane derivatives |
| 03/17/2004 | EP1240201A4 Oxidized apolipoproteins and methods of use |
| 03/17/2004 | EP1224175B1 Benzodiazepine derivatives as metabotropic glutamate receptor antagonists |
| 03/17/2004 | EP1192154B1 Bispidine compounds useful in the treatment of cardiac arrhythmias |
| 03/17/2004 | EP1147102B1 Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors |
| 03/17/2004 | EP1146865B9 Pharmaceutical composition comprising a combination of dextro- and laevo- isomers of sotalol |
| 03/17/2004 | EP1144413B1 2,5-diazabicyclo 2.2.1]heptane derivatives, their preparation and therapeutic uses |
| 03/17/2004 | EP1144365B1 Inhibitors of alpha-4 beta-1 mediated cell adhesion |
| 03/17/2004 | EP1140936B1 Tricyclic inhibitors of poly(adp-ribose) polymerases |